Trading update first quarter of 2015 Ger van Jeveren, CEO Jan Peeters, CFO 9 April 2015 Fagron Group x 1,000 euros Fagron HL Technology Total Q1 2015 114,952 2,848 117,800 Q1 2014 88,274 2,494 90,768 Total growth 30.2% 14.2% 29.8% Total Organic Organic growth growth growth CER CER 23.1% 16.8% 10.5% 0.1% 14.2% 0.1% 22.5% 16.8% 10.2% CER = constant exchange rates Excellent start of the year Total growth of 29.8% and organic growth of 16.8%! Very strong growth at FCS, the segment with the highest margin Continued focus in 2015 on robust organic growth, an active buy-and-build strategy and the construction of GMP-compliant compounding facilities Outlook for 2015 reconfirmed 1 Our unique position in global compounding Global market leadership • Optimising and innovating compounding • Extensive R&D pipeline • Unique business model • Strong brand names • Global footprint • Global buy-and-build strategy Group strengths • In-depth compounding knowledge • Use best practices • Speed of execution • Extensive global network • Local market expertise • Acquiring and integrating expertise • Solid financial position Operational performance • Global scale benefits • Compliant to highest quality standards • Product portfolio optimisation • Centralised purchasing • Production efficiency • Consolidation of activities 2 Fagron business model In % of total turnover Q1 2015 Q1 2014 37.2% 22.4% 10.1% 12.1% 52.7% 65.5% Sterile and aseptic compounding FCS Fagron Advanced Derma SyrSpend® SF Fagron Aseptic Pack Raw materials Excipients Equipment Supplies Fagron Trademarks Fagron Compounding Essentials 3 Fagron Compounding Services x 1,000 euros Fagron Compounding Services Q1 2015 42,815 Q1 2014 19,778 Total growth Tot. growth at CER 116.5% Org. growth 101.8% 41.7% Org. growth at CER 32.1% Strong turnover growth of 116.5% (organic growth of 41.7%) Driven by increasing demand for sterile compounding Compliant with the highest, most stringent quality standards Highest margin segment New antibiotic facility in NL will open in June 2015 New sterile facility in US will open in January 2016 More hospitals ready to outsource compounding Actively looking into potential acquisition targets 4 Fagron Trademarks x 1,000 euros Fagron Trademarks Q1 2015 11,594 Q1 2014 10,658 Total growth 8.8% Tot. growth at CER 4.6% Org. growth at CER 8.8% 4.6% Org. growth Turnover growth of 8.8% Driven by the global launch of Fagron Advanced Derma and SyrSpend® SF Global Fagron R&D network of 300 pharmacists and 45 researchers Global presence boosts cross selling and innovation Strong and extensive R&D pipeline R&D pipeline includes concepts on psoriasis, alopecia, pain and obesity 5 Fagron Compounding Essentials x 1,000 euros Q1 2015 Fagron Essentials Q1 2014 60,543 57,838 Total growth 4.7% Tot. growth at CER -0.4% Org. growth at CER 5.3% 0.2% Org. growth Turnover growth of 4.7% (organic growth of 5.3%) Improvement of margins due to: • Product portfolio optimisation • Centralised purchasing • Production efficiency • Focus on innovations Potential add-on acquisitions in existing markets identified 6 War chest for acquisitions 2015: 100 million euros Assumptions: Current outlook of 500 million euros of Sales with REBITDA-margin of 26% EBITDA / free cash flow conversion of 50% Average acquisition multiple of 5.5x EBITDA Including Corilus proceeds (realised in March 2015) After payment of dividend of 1.00 euro per share Earn-out payments of past acquisitions of max. 45 million euros in 2015 7 Outlook 2015 Fagron expects to realise a turnover from continuing operations of at least € 500 million1 with a REBITDA-margin2 from continuing operations of 26% 1 2 Based on constant exchange rates (euro/US dollar of 1.250 and euro/Brazilian real of 3.100). EBITDA before non-recurrent result. 8 Q&A Disclaimer This presentation may contain forward-looking statements with respect to Fagron’s future (financial) performance and position. Such statements are based on current expectations, estimates and projections of Fagron and information currently available to the company. Fagron cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. Fagron has no obligation to update the statements contained in this presentation, unless required by law. The numbers presented are not audited numbers. A more comprehensive discussion of the risk factors affecting Fagron business can be found in the company’s latest Annual Report, which can be found on the company's corporate website, www.fagron.com. 10
© Copyright 2024